Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype

References

• Bloomfield C D, Lawrence D, Byrd J C, Carroll A, Pettenati M J, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179
   PubMed Web of Science ®Google Scholar
• Byrd J C, Ruppert A S, Mrozek K, Carroll A J, Edwards C G, Arthur D C, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004; 22: 1087–1094
   PubMed Web of Science ®Google Scholar
• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Bishop J F, Matthews J P, Young G A, Szer J, Gillett A, Joshua D, et al. A randomised study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]. Blood 1996; 87: 1710–1717
   PubMed Web of Science ®Google Scholar
• Weick J K, Kopecky K J, Appelbaum F R, Head D R, Kingsbury L L, Balcerzak S P, et al. A randomised investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–2851
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomised trial by the German AML Cooperative Group. Blood 1999; 93: 4116–4124
   PubMed Web of Science ®Google Scholar
• Phillips G L, Reece D E, Shepherd J D, Barnett M J, Brown R A, Frei-Lahr D A, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–1435
   PubMed Web of Science ®Google Scholar
• Bradstock K F, Matthews J P, Lowenthal R M, Baxter H, Catalano J, Brighton T, et al. A randomised trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481–488
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Barnett M J, Horsman D E, Conneally E A, Nantel S H, Nevill T J, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002; 8: 435–443
   PubMed Web of Science ®Google Scholar
• Fung H C, Stein A, Slovak M, O'Donnell M R, Snyder D S, Cohen S, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003; 9: 766–771
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury G J, Kulkarni S, et al. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?. Bone Marrow Transplant 2003; 32: 157–164
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Treleaven J, Swansbury G J, Kulkarni S, Saso R, et al. The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy. Leuk Lymphoma 1999; 34(5–6)553–560
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, et al. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia. Semin Hematol 1996; 33(4 Suppl 3)18–23
   PubMed Web of Science ®Google Scholar
• Hann I M, Stevens R F, Goldstone A H, Rees J KH, Wheatley K, Gray R G, et al. Randomised comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10). Blood 1997; 89: 2311–2318
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499–506
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612á patients entered into the MRC AML 10áTrial. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Burnett A K, Goldstone A H, Stevens R M, Hann I M, Rees J K, Gray R G, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Harrington D P, Appelbaum F R, Lazarus H M, Rowe J M, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656
   PubMed Web of Science ®Google Scholar
• Vey N, Bouabdallah R, Stoppa A, Faucher C, Lafage M, Chabannon C, et al. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution. Bone Marrow Transplant 2004; 33: 177–182
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Perez W S, Klein J P, Kollman C, Bate-Boyle B, Bredeson C N, et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 2006; 132: 755–769
   PubMed Web of Science ®Google Scholar
• Schlenk R F, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918
   PubMed Web of Science ®Google Scholar